Daniel Swish­er leaves an ail­ing Sune­sis and swoops in to lead Jazz Phar­ma­ceu­ti­cals

Daniel Swish­er, the CEO of the strug­gling Sune­sis Phar­ma­ceu­ti­cals, has been re­cruit­ed to glob­al bio­phar­ma Jazz Phar­ma­ceu­ti­cals as the com­pa­ny’s new pres­i­dent and chief op­er­a­tions of­fi­cer.

Swish­er is tak­ing over the spot from Rus­sell Cox, who’s re­signed from the Dublin com­pa­ny to lead an un­named bio­phar­ma­ceu­ti­cal com­pa­ny work­ing in liv­er dis­ease as CEO. Swish­er will start in the new role just af­ter the hol­i­days.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER